India markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
268.18+5.05 (+1.92%)
At close: 4:00PM EDT

267.00 -1.18 (-0.44%)
After hours: 6:29PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close263.13
Open264.10
Bid263.00 x 900
Ask268.00 x 800
Day's range260.52 - 268.91
52-week range165.23 - 306.08
Volume1,258,324
Avg. volume1,318,617
Market cap69.852B
Beta (5Y monthly)0.85
PE ratio (TTM)33.85
EPS (TTM)7.92
Earnings date28-Oct-2020 - 02-Nov-2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est306.43
  • FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
    Business Wire

    FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age

    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages four months to less than six months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO based on clinical and/or in vitro assay data. KALYDECO is already approved in the U.S. and EU for the treatment of CF in patients ages six months and older.

  • Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators
    Business Wire

    Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators

    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA open-label extension study, which showed safety and efficacy consistent with the results of the Phase 3 pivotal studies in patients with CF ages 12 and older with F508del/Minimal Function (F/MF) or F508del/F508del (F/F) genotypes. Four additional scientific abstracts for ORKAMBI® and TRIKAFTA® were published in the Journal of Cystic Fibrosis as part of the ECFS conference. In addition, six scientific presentations will occur at NACFC regarding KALYDECO,® ORKAMBI and TRIKAFTA, including new data from KALYDECO in infants ages 4 to less than 6 months old.

  • CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status
    Zacks

    CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status

    CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.